from fermentation broth of Streptomyces sandaensis. Its antitumor activities were studied and compared with that of mitomycin C (MMC) in animals. FR-900482 in doses of 0.32l Omg/kg (ip) prolonged the life of mice bearing ascitic P388, L1210, B16, MM46, Ehrlich or EL4 tumors and rats bearing ascitic AH130or AMC60tumors. FR-900482 in doses of 5.6~18 mg/kg (iv) inhibited human LX-1, MX-1, SC-6 and LC-6 tumors xenografted sc in nude mice. FR-900482was more effective than or equally effective to MMC in all the tumors used. FR-900482 was ineffective against cyclophosphamide-resistant P388, but was effective against MMC-or vincristine-resistant P388. The results suggest that FR-900482 may have clinical potential.
The new antibiotic, FR-900482, found and isolated in our Research Laboratories from Streptomyces sandaensis No. 68971) , has a unique chemical structure of 4-formyl-6,9-dihydroxy-14-oxa-l ,l laiazatexracycio l /.4.i.u** à".uiu»"jtetraaeca -z,4, otriene-8-ylmethyl carbamate ( Fig. 1 ) 2). FR-900482 was shown to have good antitumor effects in transplantable tumor systems.
In this paper, we describe the antitumor activities of FR-900482 on various implanted mouseand rat tumors, and on humantumors xenografted to nude mice, and compare the effects with those of mitomycin C (MMC).
Materials and Methods
Drugs FR-900482 was prepared in our Research Laboratories. MMC was purchased from Kyow* Hakko Kogyo Co., Ltd., Tokyo. Cyclophosphamide (CPM) and vincristine (VCR) were purchasec from Shionogi & Co., Ltd., Osaka. The drugs were dissolved in or diluted with saline just before use. The solutions were given ip or iv at a volumeof 10 ml/kg body weight. Saline was given to the control animals.
Animals
Female mice of BDF2 (C57BL/6 XDBA/2), CDF, (BALB/c XDBA/2), DBA/2, C57BL/6, C3Hy
HeNand ICR strains, and male mice of BALB/cnu/nu strain were purchased from Charles Rivei Japan Inc., Atsugi. Female rats of Donryu and ACI/N strains were purchased from Shizuoka Agri-cultural Cooperative Association for Experimental Animals, Hamamatsu, and Hoshino Lab Animals, Yashio, respectively. Tumors P388 and L1210 leukemia were maintained ip by serial passage in DBA/2mice. B16 melanoma (B16) was maintained ip by serial passage in C57BL/6 mice. MM46mammarycarcinoma (MM46) was maintained ip by serial passage in C3H/HeNmice. Ehrlich carcinoma (Ehrlich) was maintained ip by serial passage in ICR mice. EL4 lymphoma (EL4) was maintained ip by serial passage in C57BL/6 mice. P388/MMC, P388/CPM and P388/VCR leukemias (P388/MMC, P388/CPM and P388/VCR) were maintained ip by serial passage in CDFXmice. AH130 hepatoma (AH130) and AMC60fibrosarcoma (AMC60)were maintained ip by serial passage in Donryu and ACI/N rats, respectively. Human LX-1 and LC-6-JCK lung carcinomas (LX-1 and LC-6-JCK), MX-1 mammary carcinoma (MX-1), and SC-6-JCK stomach carcinoma (SC-6-JCK) were maintained sc by serial passage in BALB/cnu/nu mice. The species and strain of animals, inoculum site and size, and route and schedule of drug injection used for drug evaluation tests are listed in Table 1 .
Evaluation of Antitumor Activity
Drug efficacy against the ascitic tumors was assessed as percent of median (mean) survival time of the treated group (T) to that of the control group (C).
T/C (%) Median (mean) survival time of (T) (mean) survival time of (C) xlOO Tumor weight, as derived from caliper measurements of the length and width of tumors, was calculated by the formula: Tumorweight (mg)=l/2 xa xb2, where a represents the length and b represents the width (mm).
In the experiments on humansolid tumors, initial and final tumor weights were calculated on the first injection day (just before dosing) and the last evaluation day, respectively. Relative mean tumor weight are shown for each group of mice.
Relative mean tumor weight = Meantumor weight (final)/Mean tumor weight (initial)
Drug efficacy was expressed as percent of meantumor weight of the treated group (T) to that of the control group (C).
Growth inhibition ( %)
Relative mean tumor weight (T) Relative mean tumor weight (C) xlOO 
Results

Antitumor Activity Against Ascitic Tumors in Mice and Rats
The antitumor activity of FR-900482 against 6 kinds of mouse ascitic tumors is shown in Tables  2 and 3 . The tumors were inoculated ip to mice on day 0. In the experiment reported in Table 2 , the drugs were given ip to mice once a day for 5 days (days 1~5) in the test on P388, and once a day for 9 days (days 1~9) in the tests on L1210 and B16. Both drugs dose dependency prolonged the life of mice bearing P388; the highest T/Cs were 305% for FR-900482 and 200% for MMC.Against L1210, FR-900482 showed antitumor activity at doses of 3.2 and 10 mg/kg but MMCwas active only at 1.0 mg/kg. FR-900482 was more active than MMCagainst B16.
In the experiments reported in Table 3 , the drugs were given ip to mice once a day on days 1, 5 and 9. FR-900482 was potently active against the 3 kinds of tumors tested, with antitumor effects comparable to those of MMC against MM46 and Ehrlich. The drug was more active than MMC against EL4. Table 4 shows the antitumor activities of FR-900482 and MMC against rat ascitic tumors AH130 Tumor cells were inoculated ip to mice on day 0 and drugs were given ip to the mice. Median survival times in mice bearing P388 and B16, and mean survival times in mice bearing L1210 were measured. Median survival times of control groups with P388 and B16 were 10 and 13 days, respectively. Mean survival time of control group with L1210 was 8.1 days. Twelve and 6 mice were used in control and drug treated groups, respectively, in P388 test. Twenty and 10 mice were used in control and drug treated groups, respectively, in LI210 and B16 tests. Numbers in parentheses indicate the number of survivors on day 36 in P388 test, on day 31 in L1210 test and on day 60 in B16 test. Table 3 . Antitumor effects of FR-900482against murine ascitic tumors. 118 (2) >300 (9) >300 (7) 105 (2) >300 (9) >300 (9) 195 (2) 105 143 (4) >270 (10) >270 (6) 108 >149 (3) >270 (7) >270 (9) 96 108 135 169 (3) 92 85
Tumor cells were inoculated ip to mice on day 0 and drugs were given ip to the mice. Median survival times in mice bearing tumors were measured. Median survival times of control groups were as follows: MM46; 20 days, Ehrlich; 18.5 days and EL4; 13 days. Twenty and 10 mice were used in control and drug treated groups, respectively. Numbersin parentheses indicate the number of survivors on day 60 in MM46test, on day 50 in Ehrlich test and on day 40 in EL4 test. and AMC60.The drugs were given ip on days 1, 5 and 9, and potently prolonged the life of rats bearing either kind of tumors (ip). Ninety percent of rats bearing AH130were cured by treatment with either drug, and 4 of 7 and 2 of 7 rats bearing AMC60were cured by treatment with FR-900482 and MMC, respectively.
Antitumor Activity Against Human Xenograft Tumor
The experiments were performed to evaluate the antitumor activities of FR-900482and MMC against 4 kinds of human tumors, LX-1, MX-1, SC-6-JCK and LC-6-JCK, implanted sc in BALB/c nu/nu mice. Tumor weights were measured on day 28 in the experiments on LX-1, SC-6-JCK and LC-6-JCK, and on day 27 in the experiment on MX-1. As shown in Table 5 , both drugs inhibited growth of all the tumors tested; weights of all tumors decreased by more than 90%. (mg/kg) T/C (%) T/C (%) (2) >333 (4) 172 (1) 300 (2) 183 (2) Tumor cells were inoculated ip to rats on day 0 and drugs were given ip to the rats. Median survival times in rats bearing tumors were measured. Median survival times of control groups with AH130and AMC60were 14 and 18 days, respectively. Ten and 7 rats were used per group in AH130and AMC60 tests, respectively. Numbers in parentheses indicate the number of survivors on day 60.
Toxic: <50%survivors on the final evaluation day indicates toxicity. NT: Not tested. Humantumor cells were implanted sc in BALB/cnu/nu mice on day 0 and drugs were given iv to the mice. Tumor sizes were measured on day 28 in LX-1, SC-6-JCK and LC-6-JCK tests, and on day 27 in MX-1test, and mean tumor weights were calculated. Meantumor weights of control group were as follows: LX-1 ; I,618=bl94 mg, MX-1; 732±48 mg, SC-6-JCK; 2,423±487 mg, and LC-6-JCK; l,573±170 mg (±SE). Ten and 5 mice were used in control and drug treated groups, respectively, in LX-1 and MX-1 tests. Five mice were used in each group in SC-6-JCKtest. Four and 5 mice were used in control and drug treated groups, respectively, in LC-6-JCK test.
Toxic: See Table 4 .
Antitumor Activity Against Drug-resistant P388
This experiment was performed to examine FR-900482 for cross resistance to other chemotherapeutic drugs for antitumor activities.
The results are shown in Table 6 . FR-900482 was active against P388 which is either sensitive or resistant to MMC, whereas MMC was active against MMC sensitive P388 but not against MMC-resistant P388. Tumor cells were inoculated ip to mice on day 0, and drugs were given ip to the mice on day 1. Median survival times in mice bearing tumor were measured. Median survival times of control group were ll.0 day in P388/MMC test, 9 day in P388/CPM test, and 10 day in P388/VCR and P388/S tests. Six mice were used in each group in all the tests. P388/MMC:Mitomycin C-resistant P388, P388/CPM: Cyclophosphamide-resistant P388, P388/VCR : Vincristine-resistant P388, P388/S : Non-resistant P388.
of new antitumor drugs3~6). Webelieve that the clinical effects of FR-900482 on a wide variety of tumors will be comparable to those of MMC,because we found that FR-900482 was active against murine leukemia, lymphoma, fibrosarcoma, melanoma, hepatoma, and mammary carcinoma, and human lung, mammaryand stomach carcinomas. Against all of these tumors, FR-900482 was equally active to or moreactive than MMC. Regardingour results on the prolongation of the life of mice bearing MMC-or VCR-resistant tumors, Inaba et alP suggested that in anthracycline-resistant P388 cells, an active outward transport mechanism for drugs is involved in imparting resistance to the cytostatic and cytotoxic effects of drugs. Tsuruo et alP reported that verapamil, a Ca++ antagonist, overcame the drug resistance of tumor cells and produced renewed drug sensitivity of drug-resistant tumor cells by blocking the drug efflux process in the cells. Wedo not know why FR-900482 was active against MMC-and VCR-resistant P388 cells, but suppose that its modeof action is different from that of MMCor VCR.If this be the case, FR-900482 may possess a wider, or at least different antitumor spectrum from that of MMC or VCR,which are drugs of proven clinical effectiveness.
